GlassScriptPhysician profile
Akshay Amaraneni
NPI 1306285267
$92,538.01
in general payments reported to CMS, 2019-2025
63 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,503 · 2020: $7,217 · 2021: $7,010 · 2022: $40K · 2023: $27K · 2024: $5,900 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $5,463 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,744 · Food and Beverage: $3,281 · Travel and Lodging: $2,038 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,973.00 |
| Honoraria | $5,463.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,744.00 |
| Food and Beverage | $3,280.66 |
| Travel and Lodging | $2,037.82 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $42,701.96 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $24,337.84 | 2020-2023 | Monoferric |
| Kite Pharma, INC. | $10,819.29 | 2019-2022 | |
| Hema Biologics, LLC | $6,026.58 | 2023-2025 | Sevenfact, Sevenfact |
| Adaptive Biotechnologies Corporation | $1,400.00 | 2025 | Clonoseq |
| Janssen Biotech, INC. | $585.26 | 2019-2025 | Darzalex, Tecvayli |
| Amgen INC. | $462.01 | 2019-2025 | |
| Incyte Corporation | $455.23 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $404.76 | 2019-2024 | Lynparza, Keytruda |
| Genzyme Corporation | $371.49 | 2019-2025 | |
| Abbvie INC. | $363.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $305.95 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Astellas Pharma US INC | $284.49 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $274.67 | 2019-2025 | Pyrukynd |
| Pfizer INC. | $264.53 | 2019-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshay Amaraneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.